Factive (gemifloxacin mesylate)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 BOX WARNING (revised) WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY,...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts